B-Type Natriuretic Peptide (BNP) in Heart Failure

B-type natriuretic peptide (BNP) is a hormone produced mainly by the heart’s ventricles in response to stretching of the muscle wall, and it serves as one of the most widely used blood markers for detecting and monitoring heart failure. When heart muscle cells are put under abnormal pressure or volume, they ramp up production of BNP, which then enters the bloodstream at levels that can be measured with a simple blood draw. That measurement gives clinicians a quick, objective window into how much stress the heart is under, but reading the number correctly requires understanding the many factors that push BNP up or pull it down for reasons that have nothing to do with heart failure.

How BNP Is Made

The story starts inside the cells of the heart’s lower chambers. When those muscle cells are stretched beyond their normal range, they produce a large precursor molecule called preproBNP. That precursor is clipped into a smaller molecule, proBNP, which is then split into two fragments before being released into the blood: the biologically active BNP hormone and an inactive leftover piece called NT-proBNP (N-terminal proBNP).¹ Both fragments circulate together, and both can be measured by lab tests, but they behave differently in the body and are not interchangeable.

The main trigger for this whole process is mechanical stretch of the heart wall. In heart failure, the ventricles struggle to pump efficiently, so blood backs up and the walls distend. That distension is the signal that flips on BNP production.² But stretch is not the only stimulus. Neurohormonal activation and low oxygen levels also contribute, and research in patients with aortic stenosis has confirmed that both the pumping load and the filling load on the heart independently drive BNP levels upward.³ Tissues outside the heart, including brain and kidney cells, also produce small amounts of natriuretic peptides, though the heart is by far the dominant source in clinical settings.⁴

What BNP Does in the Body

Once BNP enters the bloodstream, it acts as a counter-regulatory hormone, pushing back against the forces that make heart failure worse. It binds to a receptor on the surface of target cells and triggers production of a signaling molecule called cGMP inside those cells.⁵ The downstream effects are broad: blood vessels relax, the kidneys excrete more sodium and water, blood pressure drops, and the growth signals that cause the heart muscle to thicken are partially suppressed. In essence, BNP is the heart’s own distress signal and first-aid kit rolled into one. The hormone tries to offload the excess fluid and pressure that caused the stretch in the first place.

This built-in protective role distinguishes BNP from a passive leak marker like troponin, which spills out of damaged heart cells. BNP is actively manufactured and secreted in proportion to wall stress, and its biological job is to reduce that stress. The body clears BNP through the kidneys, with the renal extraction ratio sitting at roughly 15 to 20 percent for both BNP and NT-proBNP in healthy individuals.⁶ This renal clearance matters a great deal when interpreting test results, as kidney disease can cause levels to pile up.

How BNP Differs from ANP

BNP has a close relative: atrial natriuretic peptide (ANP), which was discovered first and comes primarily from the heart’s upper chambers, the atria. In healthy adults, ANP is released from the atria while BNP is secreted mainly from the ventricles.⁷ When heart failure develops, both peptides increase, and the left ventricle starts contributing more ANP as well. Despite their similar blood-pressure-lowering effects, the two hormones have somewhat different local roles: ANP acts in a broader endocrine fashion to lower blood pressure and reduce cardiac enlargement, while BNP appears to have a more pronounced local effect in reducing scar-tissue buildup in the ventricles.⁸ Clinically, though, BNP and NT-proBNP have become the go-to markers for heart failure diagnosis because their levels rise more dramatically and proportionally with ventricular dysfunction.

Diagnosing Heart Failure in the Emergency Room

The most familiar clinical use of BNP testing is in the emergency department, where a patient arrives short of breath and clinicians need to quickly determine whether heart failure is the cause. A systematic review of studies in acute-care settings found that BNP tests had a pooled sensitivity around 97 percent and specificity around 70 percent for identifying heart failure, with NT-proBNP performing in a similar range.⁹ Those numbers mean the test is very good at catching heart failure when it is present (few missed cases) but somewhat less precise at ruling it out when the breathlessness has another cause.

In practice, a BNP level at or above 100 pg/mL has been widely adopted as a decision threshold. One hospital study found that this cutoff yielded about 94 percent sensitivity and 75 percent specificity, with an overall diagnostic accuracy of 86 percent.¹⁰ The diagnostic performance dips slightly in older patients and in women, who naturally carry higher BNP levels. One study found the area under the curve for diagnosing heart failure was 0.86 in women and 0.90 in men, and 0.82 in patients 76 or older versus 0.88 in younger patients.¹¹

Point-of-care BNP assays, which return results at the bedside in minutes, have been shown to speed up triage times in emergency settings.¹² Their biggest practical impact comes when heart failure was not the doctor’s leading diagnosis: an unexpectedly high BNP can redirect the workup and change the treatment plan.¹³

Predicting Outcomes Over Time

Beyond the initial diagnosis, BNP and NT-proBNP levels carry strong prognostic weight. In a registry of patients with chronic heart failure, those whose NT-proBNP stayed below 125 pg/mL had very few adverse events over two years (about 3 percent), while events rose steeply at higher levels, reaching over 60 percent in the small group with levels above 10,000 pg/mL.¹⁴ That dose-response relationship holds up even in patients whose heart function has apparently recovered. A recent study found that even mildly elevated NT-proBNP (125 to 299 pg/mL) in patients with recovered pumping strength was linked to a 46 percent higher risk of relapse and an 82 percent higher risk of a composite bad outcome compared with normal levels.¹⁵

Tracking the trend over time adds even more information. In a trial of patients with reduced pumping strength, each doubling of a single baseline NT-proBNP measurement was associated with a 17 percent rise in the risk of cardiovascular death or heart failure hospitalization. When repeated measurements were factored in, that figure jumped to 66 percent per doubling, with the rise in peptide levels typically occurring well before the clinical event.¹⁶ In other words, a climbing NT-proBNP often signals trouble before symptoms worsen.

What Pushes BNP Up or Down Besides Heart Failure

Interpreting a BNP result requires knowing the conditions that can raise or lower the number independently of cardiac function. Kidney disease is one of the most common confounders. Both BNP and NT-proBNP climb as kidney filtration declines, with NT-proBNP levels rising roughly 38 percent for every 10-unit drop in estimated filtration rate compared with about 21 percent for BNP.¹⁷ In advanced kidney disease, clearance of NT-proBNP drops substantially, and researchers have argued that cutoff values should be adjusted upward for patients with impaired kidneys.¹⁸ Without that adjustment, a moderately high level could be falsely attributed to heart failure when the kidneys are the real culprit.¹⁹

Obesity pulls BNP in the opposite direction. Patients with higher body mass index consistently show lower BNP levels than leaner patients with the same severity of heart failure. One study found average BNP levels of about 205 pg/mL in obese heart failure patients versus 335 pg/mL in non-obese patients, despite similar disease severity.²⁰ The mechanisms are still debated, but the clinical implication is clear: a “normal” BNP in a very heavy patient does not necessarily rule out heart failure.²¹

Age and sex also shift baseline values. Even in healthy people, BNP rises with age and runs higher in women than in men, meaning that age- and sex-specific reference ranges are needed for accurate interpretation.²² Women tend to have higher natriuretic peptide levels even in the absence of any cardiac disease.²³

Non-cardiac conditions can also send BNP levels climbing. Sepsis, acute lung injury, and various critical illness states are known to raise BNP, which limits its usefulness as a standalone marker in the intensive care unit.²⁴ BNP has even been studied as a prognostic indicator in septic shock, though the overlap with cardiac causes of elevation means it cannot be relied on as the sole biomarker in that setting.²⁵

How Medications Complicate the Picture

A specific drug interaction that trips up clinicians involves sacubitril/valsartan, a combination medication widely prescribed for heart failure. Sacubitril blocks neprilysin, the enzyme that breaks down BNP. That means patients on this drug can show rising BNP levels even while their heart failure is improving, because the drug is preventing the hormone from being degraded. In the PARADIGM-HF trial, median BNP rose from about 202 to 235 pg/mL in the first two to three months of treatment. About 18 percent of patients saw their BNP double, and 6 percent saw it triple, even as clinical outcomes improved.²⁶

NT-proBNP is not broken down by neprilysin, so it is unaffected by this drug-related artifact. For patients on sacubitril/valsartan, NT-proBNP is therefore the preferred marker. One study confirmed that NT-proBNP and the precursor proBNP both decreased with treatment while total BNP stayed flat or rose modestly, and patients who responded well to the medication showed smaller changes across all natriuretic peptide levels than non-responders.²⁷

Using BNP to Guide Treatment Decisions

A natural question is whether doctors can use BNP or NT-proBNP like a thermostat, adjusting medications upward until the peptide level comes down to a target. This idea, called biomarker-guided therapy, has been tested in several clinical trials with mixed and ultimately inconclusive results. A large multicenter trial called GUIDE-IT compared NT-proBNP-guided management against standard care in high-risk patients and found no benefit from peptide-guided treatment.²⁸

Earlier, the TIME-CHF trial found that NT-proBNP-guided therapy reduced heart failure hospitalizations compared with symptom-guided care, but only in patients aged 60 to 75. In patients over 75, the strategy made no difference.²⁹ A 2025 meta-analysis pooling the available trials found that biomarker-guided therapy was associated with a 16 percent reduction in all-cause mortality and a 21 percent reduction in heart failure hospitalizations, but those benefits faded when the analysis was restricted to higher-quality studies, and statistical tests suggested the evidence base may still be too thin for a definitive verdict.³⁰ So the question remains open. Most guidelines endorse tracking BNP trends for risk assessment but stop short of recommending specific peptide-level targets to titrate drugs against.

Combining BNP with Other Markers

No single blood test captures everything happening in a failing heart, and researchers have increasingly looked at multi-marker panels. Combining BNP with cardiac troponin, the protein that leaks when heart muscle cells are damaged, can sort patients into low-, medium-, and high-risk groups more accurately than either marker alone. An early study in hospitalized heart failure patients found that a troponin T above a critical threshold, a BNP above 440 pg/mL, or both, stratified patients into categories with meaningfully different rates of death and cardiac events.³¹

More recent work has added a third marker, soluble ST2 (a protein linked to cardiac inflammation and fibrosis), to the mix. A 15-year retrospective study of patients with type 2 diabetes found that a composite “cardiac score” combining soluble ST2, high-sensitivity troponin, and NT-proBNP was significantly associated with both overall death and cardiovascular events, outperforming any one marker in isolation.³² Multi-marker strategies are still more common in research than in routine practice, but the trend is toward richer, layered risk profiles rather than reliance on a single number.

Nesiritide and BNP as a Drug

The idea that BNP is a protective hormone naturally led researchers to ask whether giving it as a medication could help acutely decompensated heart failure patients. The result was nesiritide, a recombinant (lab-made) form of human BNP approved for intravenous use. Early trials showed it stabilized blood pressure and improved symptoms more quickly than nitroglycerin, with a side-effect profile that was generally more favorable than dobutamine, a commonly used pump-stimulating drug.³³ However, its most common adverse effect, a drop in blood pressure, limited dosing flexibility. And a randomized controlled trial specifically assessing kidney safety found that nesiritide had no impact on renal function in patients with existing kidney impairment, easing one major concern about the drug.³⁴ Over time, enthusiasm for nesiritide cooled after larger trials failed to demonstrate clear survival benefits, and it is now used less frequently than in the early 2000s.

Genetics Behind Baseline BNP Levels

Not everyone starts from the same baseline. Genetic variation in the gene that encodes BNP (called NPPB) can meaningfully shift how much of the hormone a person produces. A large study in the Atherosclerosis Risk in Communities cohort found that a common variant in the NPPB promoter region was associated with 41 percent higher mean NT-proBNP levels, lower blood pressure, less hypertension, and modestly lower cardiovascular mortality over a median follow-up of 23 years. Carriers of the high-producing version of the gene lived, on average, about eight months longer from age 50 than those with the low-producing version.³⁵ Other variants across the broader natriuretic peptide system have also been linked to differences in peptide levels and cardiovascular risk.³⁶

These findings underscore that a BNP level is not just a snapshot of cardiac stress. It is the product of wall stretch, kidney clearance, body composition, sex hormones, age, medications, and the genetic hand a person was dealt. Two patients with identical heart failure severity can produce quite different BNP numbers, which is why experienced clinicians rely on the trend over time at least as much as any single value.

Why It Is Called “Brain” Natriuretic Peptide

The name confuses people who hear it for the first time, and understandably so. BNP was first isolated from pig brains in 1988 by Sudoh and colleagues, who found a 26-amino-acid peptide with blood-pressure-lowering and sodium-excreting activity similar to ANP but encoded by a distinct gene.³⁷ They named it “brain natriuretic peptide” because that was where they found it. It was only later that researchers realized the heart’s ventricles produce far more of it than the brain does in humans. By then the name and its abbreviation had stuck. Some clinicians now prefer the retronym “B-type natriuretic peptide,” which preserves the familiar abbreviation while sidestepping the misleading anatomical label.